Search results
How AbbVie denied Americans access to fair competition for Humira
Quartz via Yahoo Finance· 1 year agoHumira, a monoclonal antibody used to treat arthritis among other conditions, is the most lucrative...
What You Need to Know About Humira's Low-Cost Competitors
Verywell Health via Yahoo News· 9 months agoAt least nine Humira biosimilars are coming to market, along with promises of lower costs for...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters via Yahoo Finance· 2 weeks agoTeva Pharmaceutical Industries said it was set to launch its long awaited biosimilar of AbbVie's...
AbbVie's Botox, dermal fillers face slowdown jitters
Reuters via Yahoo Finance· 2 years ago(Reuters) -Demand for AbbVie Inc's Botox anti-wrinkle injection and the popular facial filler Juvederm would be hit well into the next year by inflation...
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
Motley Fool via Yahoo Finance· 4 months agoThere's one constant you can always rely on. Regardless of what's happening to the overall economy,...
Which Stock Is More Likely to Double Your Money First: Moderna or AbbVie?
Motley Fool· 2 years agoTake the case of AbbVie (NYSE: ABBV) and Moderna (NASDAQ: MRNA). AbbVie spun off from Abbott...
Is AbbVie Still a Good Dividend Stock to Buy?
Motley Fool· 7 months agoUnfortunately for shareholders of AbbVie (NYSE: ABBV), the drugmaker's top-selling product, Humira, lost patent-protected market exclusivity in the U.S....
Is AbbVie a Good Dividend Stock to Buy on the Dip?
Motley Fool· 1 year agoThe week that ended Jan. 13 was a relatively good one for the stock market overall. Is AbbVie's recent dip the first of many, or could it be an...
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Motley Fool via Yahoo Finance· 4 months agoNow that 2023 is firmly in the rearview, we can say without a doubt that it was a remarkable year...
1 Wall Street Analyst Thinks AbbVie Stock Is Going to $200. Is It a Buy at Around $165?
Motley Fool via Yahoo Finance· 4 days agoWall Street is feeling pretty good about AbbVie's (NYSE: ABBV) performance in 2024 so far. Louise...